Why the study?
Does the single-pill triple combination of aliskiren, amlodipine, and hydrochlorothiazide safely and effectively lower blood pressure in patients with hypertension who fail dual combination therapy?
Does the single-pill triple combination of aliskiren, amlodipine, and hydrochlorothiazide safely and effectively lower blood pressure in patients with hypertension who fail dual combination therapy?
The single-pill triple combination of aliskiren, amlodipine, and hydrochlorothiazide offers a safe and effective option for hypertensive patients not reaching goal blood pressure on dual therapy.
May support triple therapy after dual failure; hypothesis-generating from Level 5 evidence and requires RCTs before adoption.
Cardiovascular-related morbidity and mortality is linked to hypertension with proportional gains in cardiovascular risk factor reduction with the lowering of blood pressure. Clinical trial data has shown that attaining goal blood pressure requires, for most patients, at least two antihypertensive medications, with a significant proportion requiring regimens of three or more medications. Single-pill triple combinations have returned to the market following results of increased efficacy and adherence over dual- and mono-therapy. The combination of aliskiren, amlodipine and hydrochlorothiazide is a rational choice for combination therapy and recent studies suggest that it is safe and effective in lowering blood pressure in patients who fail dual combination therapy.
No takes yet. Share an insight, caveat, or question.
Judd et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: